By studying members of this family, we can gain a deeper understanding of the pathogenic mechanisms underlying FXS and those associated with FMRP, laying the foundation for the development of effective treatments and breakthroughs in clinical therapy. This evidence concerns the gene FMR1 and fragile X syndrome.